Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Artery Elasticity After Switch From Epzicom to Truvada
NCT00998582Phase 4Terminated
- Sponsor
- Hennepin Healthcare Research Institute
- Start
- Oct 2009
- Primary completion
- Jun 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of emtricitabine + tenofovir disoproxil in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Hennepin Healthcare Research Institute. Primary endpoints: Change in Small Artery Elasticity at 24 weeks and Change in Large Artery Elasticity at 24 weeks. Started Oct 2009; status: terminated.
02
Drugs
emtricitabine + tenofovir disoproxil
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00998582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00998582.